SPDR S&P 500 ETF Experiences Big Outflow Friday, April 26, 11:13 AM ET, by Market News Video Staff Symbols mentioned in this story: SPY, C, ORCL, DIS Exchange traded funds (ETFs) trade just ...
RSI Alert For Auxilium Pharmaceuticals Inc (AUXL) Monday, April 29, 1:11 PM ET, by Market News Video Staff Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...
By Market News Video Staff, Thursday, April 14, 3:24 PM ET
Today, Citigroup (NYSE:C) raised its price target on shares of Endo Pharmaceuticals Inc. (NASDAQ:ENDP) from $42 to $48. With the price adjustment, Citi maintained its buy rating on the Chadds Ford, Pennsylvania based company. Citi’s price adjustment comes after Endo’s recent acquisition of urology device company American Medical Systems Holdings Inc. (AMMD) for $2.6 billion, or $30 per share. Endo will incur $312 million of AMMD’s debt in the deal. As a result, “Standard & Poor's said it is putting Endo's BB+ credit ratings on CreditWatch with negative implications and expects to lower the corporate rating by one notch to BB after the deal closes while assigning a stable rating.”
According to Citi, the transaction will provide Endo with a number of underappreciated aspects such as, “1) diversification, 2) high sales growth, 3) high urology market shares and 4) expansion into ex-US markets.”
Shares of Endo Pharmaceutical are trading lower on Thursday.
Endo Pharmaceutical is a major component of the SPDR S&P Pharmaceuticals ETF (AMEX:XPH), which is trading flat at $48.91 for the day. Other top holdings of the Fund include Perrigo (NASDAQ:PRGO), Medicis Pharmaceutical (MRX) and Pfizer (NYSE:PFE).
For a complete list of holdings, visit the XPH Holdings page on ETFChannel.com
The ETF Channel Flexible Growth Investment Portfolio is designed to seek growth for investors — anywhere and everywhere. The key to the program is our portfolio strategy allows us complete flexibility in terms of asset allocation as there are no predetermined guidelines as to the level of stocks, bonds, cash, regions, countries, sectors, commodities, or even asset classes in the portfolio! In short, this is a completely flexible portfolio designed to follow the performance trail wherever it leads us.
This Article's Word Cloud:AMEXAMMDCitiContainingENDPETFsEndoFordHoldingsMedicisNYSEPRGOPharmaceuticalPharmaceuticalsPortfolioWithadjustmentafterassetassigningbasedcashcompanycompletecompletelycomponentcreditdealdebtdesignedgrowthhighholdingslistlowermaintainedmillionnotchportfoliopriceprovideratingsharestradingtransactionurologyvisitwhilewillwith
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
Daily Wrap: May 10, 2013
Daily Dividend Report: CRI, WM, CHRW, NVDA, CBI
Daily Dividend Report: MAR, LEG, ORI, OFC, RNDY
Analyst Moves: RIG, APC, BSX
Analyst Moves: DISH, MDR, PCLN
Daily Wrap: May 9, 2013